SA49 Virological Suppression in People Living with HIV-1 (PLWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups Despite Older Plwh Having Increased Rates of Comorbidities and Polypharmacy (TANDEM SUBGROUP)

A Brogan,J Slim,G Verdier,G Harper,K Mycock,H Wallis,C Donovan

doi:10.1016/j.jval.2023.03.2265

SA49 Virological Suppression in People Living with HIV-1 (PLWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups Despite Older Plwh Having Increased Rates of Comorbidities and Polypharmacy (TANDEM SUBGROUP)

A Brogan, J Slim + Show 5 more

https://doi.org/10.1016/j.jval.2023.03.2265

Copy DOI

Journal: Value in Health

Publication Date: Jun 1, 2023

Affiliation: Saint Michael's Medical Center, Adelphi Group (United Kingdom)

#People Living With HIV-1 #Suppression In People + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Aging with HIV has unique challenges, including comorbidities and drug-drug interactions. TANDEM was a retrospective medical chart review conducted across 24 US sites. This subgroup analysis examines stable-switch PLWH receiving dolutegravir/lamivudine by age.

Full Text